Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Measurable residual disease (MRD) is a critical prognostic factor in acute myeloid leukemia (AML).
• Current clinical practice faces debate regarding the optimal use of MRD for surveillance and treatment decisions in AML.
• Standardization of MRD detection and interpretation remains a challenge in the field.

Purpose of the Study:

• To review the current literature on the prognostic value and clinical application of MRD in AML.
• To identify optimal methods and timing for MRD quantification.
• To explore the impact of MRD on treatment selection, including hematopoietic stem cell transplantation (HSCT).

Main Methods:

• A comprehensive literature review was conducted using the PubMed database.
• Search terms included "MRD" or "residual disease" in recently published articles.
• Articles focusing on prognostic value, quantification techniques, and treatment implications were selected.

Main Results:

• Pre-transplant MRD status is a significant predictor of prognosis in AML.
• Various techniques and optimal timings for MRD quantification are discussed.
• MRD levels influence treatment selection, patient eligibility for HSCT, conditioning regimens, and transplant types.

Conclusions:

• MRD is an established prognostic marker in AML, guiding risk stratification.
• Further prospective, randomized studies are essential to establish definitive guidelines for MRD-guided treatment in AML, especially concerning transplantation.
• Standardizing MRD assessment and application will enhance its clinical utility in AML management.